Efficacy and Safety of ETX 018810 in Subjects With Lumbosacral Radicular Pain
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Change from baseline to Week 4 in the weekly average of the daily pain score [ Time Frame: Week 4 ]
Efficacy of ETX 018810 for the treatment of lumbosacral radicular pain will be assessed from change from baseline to Week 4 in the weekly average of the daily pain score on the 11 point Pain Intensity Numerical Rating Scale (PI NRS) from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy due to injury of the lumbosacral nerve root(s)
The subject reports at least moderate pain intensity at screening.
The subject's onset of leg pain due to LSRP is at least 3 months
The subject has a magnetic resonance imaging (MRI) scan that is normal or shows incidental lesions
The subject has a calculated creatinine clearance ≥30 mL/min
The subject has clinical laboratory values within normal limits or abnormal values that the investigator deems not clinically significant.
body mass index (BMI) <40 kg/m2.
The subject has previously undergone back surgery
The subject is unable to reliably delineate or assess pain by anatomical location/distribution on a body map.
The subject has a history of peripheral neuropathy, evidence of peripheral neuropathy, or evidence of mononeuropathy in the same limb of LSRP.
The subject has pain due to infection/abscess, hematoma, or malignancy or other pain that may interfere with the assessment of LSRP in the legs.
The subject has clinically significant and/or unstable renal, hepatic, hematologic, endocrine, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study
The subject has any neurological disease that could interfere with participation in the study (e.g., Huntington's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, seizures, epilepsy, stroke).
The subject has a history or current diagnosis of major psychiatric disorder(s)
The subject has a has a history of substance abuse or dependence
The subject has clinically significant abnormal electrocardiogram (ECG) findings
The subject has received nerve blocks and/or steroid injections for LSRP within the 3 months before screening
The subject is unwilling or unable to discontinue current medications for LSRP, including topical agents.
The subject is unable to refrain from using prohibited meds during the study, including: NSAID, antiepileptic drugs, steroids, cannabinoids, or major opioids, antidepressants, muscle relaxants, tramadol, or tapentadol.
The subject has used prohibited nonpharmacologic therapies, including acupuncture, transcutaneous electrical nerve stimulation, within 30 days the study.
The subject is currently participating in another or the same clinical study or participated in another clinical study within 3 months before screening
The subject is pregnant or lactating or not practicing adequate birth control